Sanofi-Aventis has signed a development and commercialisation deal with Regulus Therapeutics that could be worth up to $750 million to the microRNA-focused biopharmaceutical company.
The French firm will pay Regulus $25 million up front to collaborate on microRNA drug discovery and preclinical development for...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
